Last reviewed · How we verify
Metronidazole 10% ointment
At a glance
| Generic name | Metronidazole 10% ointment |
|---|---|
| Also known as | Ortem |
| Sponsor | S.L.A. Pharma AG |
| Modality | Small molecule |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- Metronidazole Ointment in Non-healing Pilonidal Sinus Wounds (PHASE2)
- Topical Versus Oral Metronidazole Following Excisional Haemorrhoidectomy (PHASE4)
- A Randomised Controlled Trial of the Use of Topical Metronidazole (10%) to Reduce Pain After Haemorrhoidectomy (PHASE2, PHASE3)
- Evaluation of Topical 10% Metronidazole Ointment for the Treatment of Active Perianal Crohn's Disease (PHASE3)
- Evaluation of the Pharmacokinetics of Metronidazole 10% Ointment Applied Peri Anally in Healthy Volunteers and Patients With Perianal Crohn's Disease (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Metronidazole 10% ointment CI brief — competitive landscape report
- Metronidazole 10% ointment updates RSS · CI watch RSS
- S.L.A. Pharma AG portfolio CI